Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 11 to 20 of 2245 total matches.

Oral Semaglutide (Rybelsus) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019  (Issue 1583)
-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA ...
An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus – Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation (Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):166-8 | Show Introduction Hide Introduction

Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
known to decrease acne. SOME ORAL CONTRACEPTIVES Drug Estrogen (µg) 1 Progestin (mg) 2 Cost 3 ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Med Lett Drugs Ther. 2000 May 15;42(1078):42-4 | Show Introduction Hide Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8 | Show Introduction Hide Introduction

Yasmin -- an Oral Contraceptive With a New Progestin

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002  (Issue 1133)
-years of use, which is similar to rates with other combination OCs. A 1-year study found 1 pregnancy ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
Med Lett Drugs Ther. 2002 Jun 24;44(1133):55-7 | Show Introduction Hide Introduction

In Brief: Calcium and Vitamin D to Prevent Osteoporotic Fractures

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012  (Issue 1393)
/day) will benefit from taking supplements.1 Table 1. Calcium Content of Some Foods1 Serving Calcium ...
The US Preventive Services Task Force (USPSTF) has issued a Draft Recommendation Statement saying, in effect, that community-dwelling women and men should not take calcium and vitamin D supplements for primary prevention of osteoporotic fractures because the evidence that they are helpful is insufficient and they increase the risk of kidney stones. The Medical Letter has said previously that there is no evidence that patients with an adequate intake of calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) will benefit from taking supplements.11. Drugs for postmenopausal osteoporosis. Treat...
Med Lett Drugs Ther. 2012 Jun 25;54(1393):52 | Show Introduction Hide Introduction

Liraglutide (Victoza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010  (Issue 1335)
) for Type 2 Diabetes Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor ...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7 | Show Introduction Hide Introduction

Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017  (Issue 1531)
-experienced patients. Mavyret is also approved for treatmentnaive patients. HCV GENOTYPES — HCV genotype 1 ...
The FDA has approved Mavyret (Abbvie) and Vosevi (Gilead), two new fixed-dose combinations of direct-acting antiviral (DAA) drugs, for treatment of chronic hepatitis C virus (HCV) infection caused by any of the six major HCV genotypes in patients without cirrhosis or with compensated cirrhosis. Both are approved for use in treatment-experienced patients. Mavyret is also approved for treatment-naive patients.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):166-70 | Show Introduction Hide Introduction

COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
oxygenation (ECMO).1 Baricitinib was previously available for this indication under an Emergency Use ...
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):e2-3 | Show Introduction Hide Introduction

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
that are chemically similar to endogenous hormones such as estradiol and progesterone.1 FDA-approved formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Med Lett Drugs Ther. 2019 Jul 1;61(1575):99-101 | Show Introduction Hide Introduction

Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
pembrolizumab (Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment ...
The FDA has approved pembrolizumab (Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (Yervoy) and, if the patient is BRAF V600 mutation positive, a BRAF inhibitor. It is the fi rst PD-1 inhibitor to be marketed in the US. Nivolumab, another PD-1 inhibitor, is available in Japan. Pembrolizumab was previously known as lambrolizumab.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):e114-5 | Show Introduction Hide Introduction